Abstract
Psoriasis and psoriatic arthritis (PsA) are chronic systemic inflammatory disorders with wide spectrums of cutaneous and musculoskeletal presentations. Management of joint disease in this population can be challenging and often requires the expertise of rheumatology in conjunction with dermatology. A multidisciplinary clinic setting may benefit these patients, and in this study we sought to evaluate the experience of such a model. We performed a retrospective chart review of patients evaluated between October 2003 and October 2009 in the Center for Skin and Related Musculoskeletal Diseases (SARM) at Brigham and Women’s Hospital, Boston, MA, USA, where patients are seen by both an attending rheumatologist and dermatologist. Main outcomes included the presence of comorbidities, accuracy of the initial diagnosis, and escalation of treatment modalities. Over the 6-year period, 510 patients were evaluated. Two hundred sixty-eight patients had psoriasis and/or PsA. The prevalence of comorbidities was high (45% hypertension, 46% hyperlipidemia, 19% diabetes, and 36% history of the past or current smoking). Visit in SARM resulted in a revised diagnosis that differed from the previous diagnosis at outside clinics in 46% of cases. Patients were more likely to receive a systemic medication after the evaluation in SARM as compared to before, 25 versus 15%, respectively, with an odds ratio of 5.1. Patients were also more likely to be treated with a biologic agent after the evaluation in SARM as compared to before, 37 versus 16%, respectively. Multidisciplinary care may facilitate the diagnosis of joint disease and offers a more comprehensive treatment approach for patients with both psoriasis and PsA. Our data can be used to support the efforts to provide integrated rheumatologic and dermatologic care for this population.
References
Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P et al (2006) Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology 45(8):1029–1038
Barra L, Pope JE, Payne M (2009) Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 36(7):1421–1428
Berthelot JM, Klarlund M, McGonagle D, Bernelot-Moens HJ, Calin A, Harrison B et al (2001) Lessons from an international survey of paper cases of 10 real patients from an early arthritis clinic. CRI (Club Rhumatismes et Inflammation) Group. J Rheumatol 28(5):975–981
Boehncke S, Fichtlscherer S, Salgo R, Garbaraviciene J, Beschmann H, Diehl S et al (2011) Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 303(6):381–388
Chandran V, Schentag CT, Gladman DD (2008) Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J Rheumatol 35(10):2069–2070
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2572
Curtis JR, Arora T, Narongroeknawin P, Taylor A, Bingham CO, Cush J et al (2010) The delivery of evidence-based preventive care for older Americans with arthritis. Arthritis Res Ther 12(4):R144
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP). JAMA 285(19):2486–2497
Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F et al (2008) The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 59(5):772–780
Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ (2004) Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 51(5):704–708
Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T et al (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53(4):573
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296(14):1735–1741
Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41(6):1103–1110
Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML (1990) Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 17(6):809–812
Gottlieb AB, Dann F (2009) Comorbidities in patients with psoriasis. Am J Med 122(12):1150 e1151–e1159
Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M (2007) Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 57(6):963–971
Ibrahim G, Waxman R, Helliwell PS (2009) The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 61(10):1373–1378
Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 42(12):1460–1468
Kavanaugh A, Antoni CE, Krueger GG, Yan S, Bala M, Dooley LT et al (2006) Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 65(4):471–477
Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A et al (2006) The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65(8):1038–1043
Kavanaugh AF, Ritchlin CT (2006) Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 33(7):1417–1421
Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR et al (2011) Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 25(2):157–163
Kurd SK, Gelfand JM (2009) The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol 60(2):218–224
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM (2010) The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 146(8):891–895
McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42(6):778–783
Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279–3289
Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264–2272
Mody E, Husni ME, Schur P, Qureshi AA (2007) Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience. Br J Dermatol 157(5):1050–1051
Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M et al (2007) German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 299(3):111–138
Onel KB, Onel K (2010) Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. Arthritis Care Res 62(7):1024–1028
Palazzi C, Olivieri I, Petricca A, Salvarani C (2002) Rheumatoid arthritis or psoriatic symmetric polyarthritis? A difficult differential diagnosis. Clin Exp Rheumatol 20(1):3–4
Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG (2009) Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145(6):700–703
Regier DA, Bansback N, Dar Santos A, Marra CA (2007) Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Rev Pharmacoecon Outcome Res 7(2):155–169
Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL (2010) Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res 62(3):345–353
Scarpa R, Cosentini E, Manguso F, Oriente A, Peluso R, Atteno M et al (2003) Clinical and genetic aspects of psoriatic arthritis “sine psoriasis”. J Rheumatol 30(12):2638–2640
Shang Q, Tam LS, Yip GW, Sanderson JE, Zhang Q, Li EK et al (2011) High prevalence of subclinical left ventricular dysfunction in patients with psoriatic arthritis. J Rheumatol 38(7):1363–1370
Solomon DH, Love TJ, Canning C, Schneeweiss S (2010) Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 69(12):2114–2117
Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG (2010) Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 146(7):721–726
Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9(2):136–139
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673
Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM (2009) Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 61(2):233–239
Conflict of interest
AAQ is a consultant for Amgen, Centocor, Novartis and Pfizer, has received a research grant from Amgen and has developed a questionnaire that was licensed to Pfizer and Merck for clinical trials. MEH is a consultant for Amgen, UCB and Pfizer, and has developed a questionnaire that was licensed to Pfizer and Merck for clinical trials.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Velez, N.F., Wei-Passanese, E.X., Husni, M.E. et al. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch Dermatol Res 304, 7–13 (2012). https://doi.org/10.1007/s00403-011-1172-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-011-1172-6